Get the Stockscreener App
8.49
0.24%
-0.02
Nuvectis Pharma Inc stock is traded at $8.49, with a volume of 17,223.
It is down -0.24% in the last 24 hours and up +9.55% over the past month.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
See More
Previous Close:
$8.51
Open:
$8.51
24h Volume:
17,223
Relative Volume:
0.18
Market Cap:
$217.21M
Revenue:
-
Net Income/Loss:
$-22.38M
P/E Ratio:
-6.0213
EPS:
-1.41
Net Cash Flow:
$-15.54M
1W Performance:
+4.69%
1M Performance:
+9.55%
6M Performance:
+9.13%
1Y Performance:
+26.15%
1-Day Range:
$8.38
$8.60
1-Week Range:
$8.08
$8.93
52-Week Range:
$5.55
$11.52
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Name
Nuvectis Pharma Inc
Sector
Industry
Phone
360-837-7232
Address
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
8.48 | 217.98M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.56 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.30 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
868.53 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
361.43 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.25 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | Maxim Group | Buy |
| Mar-17-25 | Initiated | Laidlaw | Buy |
| Jul-13-22 | Initiated | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Stock (NVCT) Latest News
Nuvectis Pharma (NASDAQ:NVCT) Trading Up 5.8%Should You Buy? - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Trading Up 5.8% – Should You Buy? - Defense World
Is Nuvectis Pharma Inc. stock a buy on dipsQuarterly Growth Report & Real-Time Volume Spike Alerts - bollywoodhelpline.com
Will Nuvectis Pharma Inc. stock outperform value stocksInsider Selling & Precise Trade Entry Recommendations - bollywoodhelpline.com
Investment Report: Will Nuvectis Pharma Inc outperform tech stocksGold Moves & Safe Capital Growth Plans - baoquankhu1.vn
Energy Moves: Is Nuvectis Pharma Inc stock a good pick for beginnersRisk Management & Low Drawdown Trading Techniques - baoquankhu1.vn
Take Profit: Can Nuvectis Pharma Inc maintain its current growth rateBreakout Watch & Smart Allocation Stock Reports - baoquankhu1.vn
Aug Spikes: Can Nuvectis Pharma Inc stock beat analyst upgradesJuly 2025 Recap & Real-Time Volume Spike Alerts - moha.gov.vn
What Wall Street predicts for Nuvectis Pharma Inc. stock price2025 Major Catalysts & Advanced Swing Trade Entry Plans - Улправда
We Think Nuvectis Pharma (NASDAQ:NVCT) Can Afford To Drive Business Growth - simplywall.st
Will Nuvectis Pharma Inc. stock benefit from commodity pricesSmall Cap Stock Opportunities & Grow Smarter With Pro-Level Research - Улправда
Why (NVCT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Laidlaw & Co. Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - MSN
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 0.5%Here's Why - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 0.5% – Here’s Why - Defense World
(NVCT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Is Nuvectis Pharma Inc a good long term investmentEx-Dividend Date Alerts & High Return Trading Strategies - earlytimes.in
Why Nuvectis Pharma Inc. stock remains on buy listsFed Meeting & Growth Focused Stock Reports - Улправда
How rising interest rates impact Nuvectis Pharma Inc. stockEarnings Growth Summary & Verified Swing Trading Watchlists - DonanımHaber
Can Nuvectis Pharma Inc. stock beat analyst upgrades2025 Earnings Impact & Daily Growth Stock Investment Tips - DonanımHaber
Will Nuvectis Pharma Inc. stock keep outperforming rivalsMarket Sentiment Report & Entry and Exit Point Strategies - DonanımHaber
Will Nuvectis Pharma Inc. stock maintain dividend yield2025 Risk Factors & Weekly Stock Breakout Alerts - DonanımHaber
Weekly Recap: Will Nuvectis Pharma Inc. stock keep outperforming rivalsMarket Trend Summary & Capital Efficient Trade Techniques - bolumsonucanavari.com
Nuvectis Pharma announces initiation of Phase 1b study of NXP900 - MSN
Nuvectis Begins Phase 1b Study to Address Drug Resistance in Lung Cancer - socialunderground.co
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib By Investing.com - Investing.com Nigeria
Positive Recommendation on Nuvectis Pharma Driven by Promising Lead Candidate and Milestone Clinical Studies - TipRanks
Nuvectis Pharma Starts Phase 1b Study With Osimertinib for Non-Small Cell Lung Cancer - marketscreener.com
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib - Investing.com
Nuvectis Pharma announces the initiation of the phase 1b study of NXP900 in combination with osimertinib in patients with NSCLC - marketscreener.com
Nuvectis Pharma Initiates Phase 1b Study of NXP900 in Combination with Osimertinib for EGFRmut+ NSCLC Patients - Quiver Quantitative
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC - Sahm
Precision Trading with Nuvectis Pharma Inc. (NVCT) Risk Zones - Stock Traders Daily
Nuvectis Pharma Shares Gain Momentum on Analyst Backing and Clinical Progress - AD HOC NEWS
Nuvectis Pharma (NVCT) Stock Analysis Report | Financials & Insights - Benzinga
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; retail investors who hold 44% profited and so did insiders - Yahoo Finance
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; individual investors who hold 44% profited and so did insiders - simplywall.st
Technical Reactions to NVCT Trends in Macro Strategies - news.stocktradersdaily.com
Nuvectis Pharma (NASDAQ:NVCT) Trading 9.8% HigherHere's What Happened - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Trading 9.8% Higher – Here’s What Happened - Defense World
Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright - Investing.com Australia
Will Nuvectis Pharma Inc. stock attract more institutional investors2025 Trade Ideas & Technical Buy Zone Confirmations - Newser
Will Nuvectis Pharma Inc. stock split attract more investors2025 Price Momentum & Scalable Portfolio Growth Ideas - Newser
Published on: 2025-11-30 11:27:46 - BỘ NỘI VỤ
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC - marketscreener.com
Nuvectis Pharma to Host a Virtual Key Opinion Leader - GlobeNewswire
Trading the Move, Not the Narrative: (NVCT) Edition - news.stocktradersdaily.com
How Nuvectis Pharma Inc. stock reacts to Fed rate cutsWeekly Profit Recap & Weekly Breakout Watchlists - newser.com
Nuvectis Pharma Inc Stock (NVCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvectis Pharma Inc Stock (NVCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sanchez Juan | Director |
Nov 05 '25 |
Buy |
5.79 |
13,000 |
75,270 |
78,150 |
| Kaplan Matthew L. | Director |
Nov 05 '25 |
Buy |
5.84 |
11,000 |
64,240 |
124,760 |
| Mosseri Marlio Charles | 10% Owner |
Oct 27 '25 |
Buy |
6.28 |
72,836 |
457,410 |
3,136,576 |
| Mosseri Marlio Charles | 10% Owner |
Oct 23 '25 |
Buy |
6.06 |
46,900 |
284,214 |
3,028,706 |
| Mosseri Marlio Charles | 10% Owner |
Oct 24 '25 |
Buy |
6.15 |
35,034 |
215,459 |
3,063,740 |
| Mosseri Marlio Charles | 10% Owner |
Jun 20 '25 |
Buy |
7.99 |
5,603 |
44,768 |
2,981,806 |
| Mosseri Marlio Charles | 10% Owner |
Jun 18 '25 |
Buy |
8.05 |
28,043 |
225,746 |
2,976,203 |
| Mosseri Marlio Charles | 10% Owner |
Jun 17 '25 |
Buy |
8.11 |
5,399 |
43,786 |
2,948,160 |
| Mosseri Marlio Charles | 10% Owner |
May 12 '25 |
Buy |
8.11 |
21,167 |
171,664 |
2,942,761 |
| Mosseri Marlio Charles | 10% Owner |
May 06 '25 |
Buy |
8.59 |
12,444 |
106,955 |
2,896,565 |
2.34%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):